Jefferies Reiterated PRA Health Sciences (NASDAQ:PRAH) As a “Buy”; They Now Have a TP Of $92.0

September 17, 2017 - By Nellie Frank

 Jefferies Reiterated PRA Health Sciences (NASDAQ:PRAH) As a

PRA Health Sciences (NASDAQ:PRAH) Rating Reaffirmed

In a research note issued to clients and investors this morning, Jefferies kept their “Buy” rating on PRA Health Sciences (NASDAQ:PRAH) shares. The PT would suggest a possible upside of 24.32 % from company’s close price.

PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage

Among 11 analysts covering PRA Health Sciences (NASDAQ:PRAH), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. PRA Health Sciences has $9400 highest and $43 lowest target. $80.43’s average target is 8.69% above currents $74 stock price. PRA Health Sciences had 21 analyst reports since July 22, 2015 according to SRatingsIntel. Citigroup upgraded it to “Buy” rating and $53 target in Wednesday, May 4 report. On Tuesday, August 8 the stock rating was maintained by Credit Suisse with “Outperform”. Citigroup maintained the stock with “Buy” rating in Thursday, September 22 report. Credit Suisse upgraded the shares of PRAH in report on Monday, February 6 to “Outperform” rating. Credit Suisse reinitiated PRA Health Sciences Inc (NASDAQ:PRAH) on Friday, August 14 with “Outperform” rating. The stock has “Neutral” rating by Credit Suisse on Tuesday, June 21. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Neutral” rating given on Tuesday, September 6 by UBS. The rating was initiated by Suntrust Robinson with “Neutral” on Thursday, November 19. The stock has “Outperform” rating by Robert W. Baird on Tuesday, August 8. The firm has “Buy” rating given on Monday, September 11 by Jefferies.

The stock increased 0.15% or $0.11 on September 15, reaching $74. About 889,908 shares traded or 4.59% up from the average. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 52.22% since September 17, 2016 and is uptrending. It has outperformed by 35.52% the S&P500.

Analysts await PRA Health Sciences Inc (NASDAQ:PRAH) to report earnings on November, 1. They expect $0.81 EPS, up 30.65 % or $0.19 from last year’s $0.62 per share. PRAH’s profit will be $50.79 million for 22.84 P/E if the $0.81 EPS becomes a reality. After $0.62 actual EPS reported by PRA Health Sciences Inc for the previous quarter, Wall Street now forecasts 30.65 % EPS growth.

PRA Health Sciences, Inc. is a contract research organization. The company has market cap of $4.64 billion. The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It has a 48.11 P/E ratio. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

More notable recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Seekingalpha.com which released: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q2 2017 Results – Earnings …” on August 12, 2017, also Globenewswire.com with their article: “PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2016 Results …” published on February 22, 2017, Globenewswire.com published: “PRA Health Sciences Named Clinical Research Company of the Year” on May 02, 2017. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) were released by: Seekingalpha.com and their article: “PRA Health Sciences Set For A Quarterly Earnings Surprise – Again” published on July 26, 2017 as well as Nasdaq.com‘s news article titled: “Insiders Roundup: Facebook, PRA Health Sciences” with publication date: August 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.